GLPG1837 dose 1
Idiopathic Pulmonary Fibrosis
Clinical trials
1
Developer
Lakefront Biotherapeutics NV
Overview
GLPG1837 dose 1 is an agent tracked by PF-Atlas in the context of idiopathic pulmonary fibrosis. It appears in 1 tracked IPF clinical trial.
GLPG1837 dose 1 clinical trials
Explore related
Medical disclaimer. This page summarizes research about GLPG1837 dose 1 for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.